TIME TO SHATTER MYTHS: Nothing Will Outperform Pot Stocks Next Year!
I’m putting the finishing touches on another year of incredible profits – it’s time to look to the next 12 months and consider the trends that will dominate 2020. Given the massive amounts of data and research I’ve been studying, it is the cannabis market that will make tremendous gains.
Global cannabis use and acceptance are growing within all consumer segments, with an estimated market size of USD$146.6 billion by 2025. If the U.S. and all 28 countries in the European Union legalize cannabis for medical and recreational use, the worldwide market for cannabis products could reach $194 billion.
Just the European medical marijuana market is FILLED with opportunities; this niche is estimated to reach $64 billion by 2028. I’ve been watching Germany closely for its medical market because the healthcare system covered over $75 million of cannabis products in 2018.
Courtesy: New Frontier
With these numbers in mind, there’s no place I’d rather be positioned right now than the global cannabis market – especially in the areas of rapid growth, like Israel, Germany, and the U.K. These are cannabis-friendly regions with strong demand; in fact, medical cannabis is already available in 10 European countries, while marijuana is now legal for medical purposes and decriminalized for recreational use in Israel.
Israel is ideal for this, actually, since export approvals are expected for Q2 of 2020, which will make Israel only the third nation in the world allowing cannabis exports. Thus, a company with operations in Israel would be well-positioned to sell the product locally while preparing to export across the European continent.
93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.
Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!
Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!
Today, there’s one and only one company that’s actually preparing to do this: Isracann Biosciences (CSE: IPOT, OTC: ISCNF), which truly is Israel’s first pure-play cannabis enterprise. Because of the country’s perfect temperatures and humidity levels for growing marijuana (much better than Canada) and low-cost production (estimated at $0.40/gram), it allows for industrial-scale cultivation and robust profits.
Even prior to exporting, Isracann has a huge market at home: 46,000 patients are already accessing medical cannabis in Israel, and that number is projected to exceed 90,000 next year. Given its ideal climate for cannabis cultivation, Israel is perfectly situated as the next cannabis capital of the world – with Isracann in the leading position in this exciting new market.
In light of this data, it’s not hard to envision Israel as the new frontier of cannabis cultivation, science, and trade. For decades, Israel has already been recognized worldwide as a center of excellence in agronomy, research, genetics, manufacturing, and quality assurance.
Being first to this market means that Isracann can achieve brand positioning with a focus on high-quality, made-in-Israel cannabis to meet both the domestic and international demand for the product. Consumers will consider Israeli cannabis the best available, and they’ll count on Isracann to grow it and ship it to them.
That’s the future of cannabis, and you’re hearing about it now before the latecomers all crowd into the trade and run the stock price up.
Chief Editor, CrushTheStreet.com
Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!
Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. Crush The Street has been compensated three hundred thousand dollars, directly by IsraCann Biosciences, for a marketing campaign. We have also participated in a private placement. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.
Please read our full disclaimer at CrushTheStreet.com/